ABSTRACT Antibodies against the lutropin receptor have been obtained by the monoclonal antibody technique. Mice were immunized with luteal membrane from ovaries from pseudopregnant rats, containing high lutropin receptor concentration. Hybridoma cells were obtained by fusing mouse myeloma cells with spleen cells from the immunized animal. Five clones were produced that secreted monoclonal antibodies that specifically inhibited lutropin binding to its receptor in a competitive fashion. Antibodies from three clones were capable of blocking biological response to lutropin (e.g., testosterone production by isolated rat Leydig cells). Antibodies secreted by two other clones, however, were capable of acting as Leydig cell stimulators. Immunofluorescence studies demonstrated the presence of receptor capping which may be associated with receptor-mediated testosterone production. Antagonist antibodies could be transformed into agonist by the addition of a second crosslinking anti-mouse IgG. The discovery of agonist antibodies against the receptor molecule proves that the biological information of the lutropin-receptor complex resides in the receptor and not in the hormone.
Advances in purification, molecular characterization, and activation of hormone receptor have been difficult because of the extremely low concentration of physiologically relevant receptor molecules in tissue. Antibodies to insulin receptors have been valuable tools in elucidating the subunit structure of the insulin receptor (1, 2) and the mechanism of receptor activation (3, 4) . However, because the antibodies are probably polyclonal, their use in associating discrete epitopes with various functions of the receptor may be difficult (5) .
The production of monoclonal antibodies (Mabs) directed against a single antigenic determinant of the receptor molecule will allow study of receptor purification as well as its structure and function.
Antibodies against hormone receptors have been shown to be antagonist or agonist, or both, with respect to the hormone (5) . These results have led to speculation that dimerization and local aggregation induced by binding of these antibodies to surface receptors plays an important role in the induction of the immediate biologic responses to peptide hormones (6) . Mabs with the agonist characteristic have been described for the epidermal growth factor (EGF), which can induce early and delayed effects of the factor (7) .
Antibodies to insulin and thyrotropin receptors have also been reported to be agonist (8, 9) . These antibodies have been detected in certain diseases. Mouse Mabs against the thyrotropin receptor are inactive as a thyroid stimulator (10) . Recently, hu- The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
man Mabs with agonist and antagonist characteristic have been described (11) .
Stimulation of DNA synthesis in fibroblasts by EGF depends on the persistent occupation of a relatively small fraction of the total measurable, externally located, binding sites for the hormone (12) . It has been suggested that hormone-receptor complexes must undergo some type of cell surface distribution and self-aggregation to elicit a biological response (13) . Cleavage of EGF with cyanogen bromide results in a unique hormone derivative which is virtually devoid of biological activity but nevertheless retains substantial binding activity. The biological activity of this inactive analogue can be restored by crosslinking with specific bivalent antibodies to EGF (13) .
In the present paper we describe two populations of bivalent lutropin receptor (LH-R) antibodies: one blocks binding but is active by itself as a Leydig cell stimulator, producing the synthesis of testosterone; the other blocks binding and biological activity (e.g., testosterone synthesis in isolated rat testis Leydig cells). The latter can be transformed into agonist by the addition of a second crosslinking anti-mouse IgG. Immunofluorescence studies demonstrated the presence of receptor capping which may be associated with testosterone synthesis, suggesting the same activation mechanism for the peptide hormone receptor, coupled or uncoupled with the adenylate cyclase complex. The finding of agonist and antagonist antibodies against the same receptor molecule could be a valuable tool in studies of the mechanism of hormone action, receptor aggregation, activation, structure, and function.
MATERIAL AND METHODS The preparation of LH-Rs followed published procedures (14) . Immature RESULTS The Mabs against LH-R were raised in an ovarian membrane preparation containing high levels of LH-R. Hybridoma clones secreting anti-LH-R were identified by using another well-known source of LH-R, the testis homogenate. One hundred forty-four hybridomas grew in 0.2-ml culture wells. Five culture supernatants were able to block '"I-LH binding to its receptors (designated Mab I2, 19, IV12, V1o, and V20). All of them have retained that capacity, and they have been subcloned repeatedly.
The binding characteristic of the interaction between receptor and anti-LH-R antibodies was studied by constructing a typical saturation curve for 125I-LH binding, with and without culture supernatant from Mabs I2, I9, IV12, V1O, and V2o. In order to observe competitive binding, the saturation curve was constructed by increasing the mass of 125L-LH without changing its specific activity, to avoid the low 125I-LH binding activity that occurs when nonlabeled LH is used for displacement. The data were plotted according to the method of Lineweaver and Burk (Fig. 1 ). The characteristic pattern described by Best-Bolpomme and Dessen (21) was apparent. According to the equation derived by these authors, the apparent Ki (Mab IV12) was 1012 M-1, 1,000 times higher than the affinity constant for LH-R binding interaction.
The competitive characteristic of the Mab IV12 anti-LH-R was supported by immunofluorescence studies. Collagenasedispersed rat testis Leydig cells (106 cells per ml) were incubated for 3 hr at 230C with culture supernatant from hybridomas secreting anti-LH-R and then with and without hLH (100 mIU/ml) for 2 hr at 340C. After the second incubation, the cell pellets were stained for direct immunofluorescence by using fluorescein-or rhodamine-conjugated anti-mouse IgG.. The plasma membrane location of LH-R is well known. Thus possible to label the receptor by using culture supernatant from positive clones showing a typical pattern for plasma membrane receptor stain (Fig. 2A) . The specificity of the labeling and the competitive characteristic of anti-LH-R antibodies was supported by the displacement in the fluorescence observed in the cell pellets incubated with hLH before the addition of fluorescein conjugated anti-mouse IgG (Fig. 2B) .
In addition to a uniform plasma membrane receptor staining, it also was possible to observe fluorescent patches of receptor ( Fig. 2A) and a typical "receptor capping" (Fig. 2 C and D) .
Fluorescent patches were observed with the five culture supernatants that were able to block 1"I-LH binding.
The observation of receptor capping as mediated by anti-LH-R antibodies led us to study the biological properties of the Mab to LH-R. (Fig. 3) .
Two hybridomas clones, Mab V1o and V20, were able to trigger specific LH-mediated biological effect (Fig. 3) . Testosterone production was observed upon addition of the antibody in absence of LH. In addition, the dose-response relationship between testosterone formation and LH concentration shows an increase in the sensitivity of Leydig cells to gonadotropin in the presence of anti-LH-R.
Concentration, time, and temperature dependences for the anti-LH-R with LH agonist characteristic are shown in Fig. 4 at 37TC. On the other hand, there was no agonist activity when incubation was performed at 23TC for 3 hr. In spite of that, Leydig cell response to LH stimulation was less sensitive but possible at 23TC (data not shown), and binding of the antibodies at 23TC also was evident (antibodies were incubated at 23TC before the addition of LH and thev were able to block 1"I-LH binding; see Fig. 1 ).
It is known that both bivalent and monovalent antibodies to the Fab fragment are competitive antagonists of insulin binding, but only the bivalent antibodies stimulate the transport and oxidation of glucose. The inactive Fab fragment regains insulinmimicking activity by the addition of a second crosslinking antibody directed against this monovalent Fab (5). In order to study the effect of a second crosslinking antibody on the antagonist activity of Mab, Leydig cells were incubated for 3 hr at 23TC
with the antagonist Mab IV12, followed by a second incubation with and without anti-mouse IgG. Testosterone production was increased 2-to 3-fold with Mab plus anti-mouse IgG. Anti-mouse IgG had no effect in the absence of Mab during the first incubation (Table 1) .
It is known that changes in the protein component of hLH such as iodination or modification of the carbohydrate side chain (22, 23) can produce some loss in the biological properties of the hormone (e.g., testosterone production) without affecting the binding of the hormone to the receptor. This led us to study the effect of a second crosslinking antibody, anti-hLH (Table 1) . It was possible to enhance the biological activity of the hLH by addition of the second crosslinking antibodies. The anti-hLH was not active by itself.
The antagonist characteristic of Mab I2, 19 , and IV12 may be due to a possible monovalent nature of these antibodies. However, as shown in Fig. 5 , antagonist Mab IV12 produced Levdig cell aggregation and some lysis when the Mab was incubated in the presence of complement, suggesting the bivalent nature of these antibodies. Mab I2, I9, and IV12 were not able to produce capping in the absence of a second crosslinking antibody.
DISCUSSION
The agonist characteristic of anti-receptor antibodies has been well established for insulin (8) , and Mabs against the receptor for EGF (insulin family molecule) have been described with agonist activity (7) . However by activation of adenyl cyclase, the only known receptor antibodies with hormone agonist characteristic are those described in Graves disease (6) or detected by Mab studies (11) .
The finding of two populations of Mabs-one that blocks LH binding and biological activity, and one that also-blocks binding but produces the biological effect-strongly suggests that within the receptor molecule there are at least two sites for LH interaction, one of them representing the-functional binding site. These results agree with the observation that structure modification in the LH molecule preserved the ability to recognize the specific receptor but completely blocked the biological response (e.g., testosterone synthesis) (22, 23) 3990 Cell Biology: Podesta et alP tibody enhancement of EGF activity in sensitive and resistant cells has been described (13) . Anti-insulin antibodies have now also been shown to enhance substantially the biological effects of this hormone in fibroblasts (24) . In close agreement with the above results, in the present study it was also possible to enhance the biological activity of the hLH by addition of the second crosslinking antibodies.
Our results support the above hypothesis suggesting the same activation mechanism for the peptide hormone receptor, coupled or uncoupled with the adenylate cyclase complex. These results are also in agreement with the idea that the biological information of the LH-receptor complex resides in the receptor and not in the hormone. Furthermore, these two populations of antibodies offer a powerful tool for studying the structure from a functional point of view.
